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Ras-induced malignant transformation requires Ras
farnesylation, a lipid posttranslational modification cat-
alyzed by farnesyltransferase (FTase). Inhibitors of this
enzyme have been shown to block Ras-dependent trans-
formation, but the mechanism by which this occurs re-
mains largely unknown. We have designed FTI-276, a
peptide mimetic of the COOH-terminal Cys-Val-Ile-Met
of K-Ras4B that inhibited potently FTase in vitro (IC50 5
500 pM) and was highly selective for FTase over gera-
nylgeranyltransferase I (GGTase I) (IC50 5 50 nM). FTI-
277, the methyl ester derivative of FTI-276, was ex-
tremely potent (IC50 5 100 nM) at inhibiting H-Ras, but
not the geranylgeranylated Rap1A processing in whole
cells. Treatment of H-Ras oncogene-transformed NIH
3T3 cells with FTI-277 blocked recruitment to the
plasma membrane and subsequent activation of the ser-
ine/threonine kinase c-Raf-1 in cells transformed by far-
nesylated Ras (H-RasF), but not geranylgeranylated,
Ras (H-RasGG). FTI-277 induced accumulation of cyto-
plasmic non-farnesylated H-Ras that was able to bind
Raf and form cytoplasmic Ras/Raf complexes in which
Raf kinase was not activated. Furthermore, FTI-277
blocked constitutive activation of mitogen-activated
protein kinase (MAPK) in H-RasF, but not H-RasGG, or
Raf-transformed cells. FTI-277 also inhibited oncogenic
K-Ras4B processing and constitutive activation of
MAPK, but the concentrations required were 100-fold
higher than those needed for H-Ras inhibition. The re-
sults demonstrate that FTI-277 blocks Ras oncogenic
signaling by accumulating inactive Ras/Raf complexes
in the cytoplasm, hence preventing constitutive activa-
tion of the MAPK cascade.
Ras proteins are plasma membrane-associated GTPases that
function as relay switches transducing biological information
from extracellular signals to the nucleus (for review, see Refs.
1–3). In normal cells, Ras proteins cycle between the GDP
(inactive)- and GTP (active)-bound forms to regulate prolifera-
tion and differentiation. The mechanism by which extracellular
signals, such as epidermal and platelet-derived growth factor,
transduce their biological information to the nucleus via Ras
proteins has recently been unraveled. Binding of these growth
factors to tyrosine kinase receptors results in autophosphoryl-
ation of various tyrosines which bind src-homology 2 (SH2)
domains of several signaling proteins. One of these, a cytoplas-
mic complex of GRB-2 and a Ras exchanger (SOS-1), is re-
cruited by the tyrosine-phosphorylated receptor, where SOS-1
catalyzes the exchange of GDP for GTP on Ras, hence activat-
ing it. GTP-bound Ras recruits c-Raf-1, a serine/threonine ki-
nase, to the plasma membrane where its kinase activity is
activated by as yet undetermined membrane-associated
events. Raf triggers a kinase cascade by phosphorylating MAP
kinase kinase (MEK) which, in turn, phosphorylates MAPK1 on
threonine and tyrosine residues. Activated MAPK translocates
to the nucleus where it phosphorylates transcription factors. In
a large number of human cancers, Ras is locked in its GTP-
bound form due to mutations in amino acids 12, 13, or 61 (4, 5).
As a result, the Ras pathway no longer requires an upstream
growth signal, is uninterrupted and the enzymes in this path-
way such as Raf, MEK, and MAPK are constitutively activated
(1–3).
In addition to its inability to hydrolyze GTP, oncogenic Ras
must associate with the plasma membrane to cause malignant
transformation (6–8). Ras membrane association is mediated
through a series of posttranslational modifications (9–12). The
first step is catalyzed by a cytosolic heterodimer farnesyltrans-
ferase (FTase), which attaches farnesyl to the thiol group of
cysteine of the carboxyl-terminal tetrapeptide CAAX, where A
is isoleucine or valine and X is serine or methionine (13–16).
Because farnesylation is required and sufficient for Ras trans-
formation (8, 17), FTase is an attractive target for the devel-
opment of a potential new class of anti-cancer agents (18, 19).
Although CAAX peptides are potent competitive inhibitors of
FTase, rapid degradation and low cellular uptake limit their
use as therapeutic agents. Over the last 3 years, we (20–22)
and others (23–26) have designed CAAX peptidomimetics that
potently inhibit FTase in vitro and Ras processing in vivo but
that retain several peptidic features. More recently, we have
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designed non-peptide CAAX mimetics that have several desir-
able features for further development as anti-cancer agents
(27). Although these non-peptide mimics and CAAX peptidomi-
metics inhibit FTase potently (nM), their ability to disrupt Ras
processing in whole cells occurs at micromolar concentrations
that would not be easily achievable in in vivo settings. There-
fore, there is a need for improved FTase inhibitors with more
potent activity in whole cells and in vivo.
Ras CAAX peptidomimetics have been shown to reverse on-
cogenic H-Ras transformation, inhibit the growth of H-Ras-
transformed, but not normal cells in culture, and slow the
growth of Ras but not Raf-transformed cells in nude mice (23,
24, 28). Recently, FTase inhibitors have also been shown to
inhibit oncogenic Ras activation of MAPK in H-Ras-trans-
formed cells (29, 30). Whether FTase inhibitors also inhibit
oncogenic K-Ras signaling is not yet known. This is an impor-
tant question, since K-Ras is a more efficient substrate for
FTase, rendering it more difficult to block by FTase inhibitors,
and since K-Ras mutations are most prevalent in human tu-
mors where Ras is mutated. Furthermore, the mechanism by
which FTase inhibitors suppress MAPK activation has not
been investigated. Specifically, the effects of FTase inhibitors
on the interactions between Ras and its downstream effectors
such as Raf have not been studied. The present work describes
the design of a highly potent (pM/nM) Ras CAAX peptidomi-
metic which antagonizes both H- and K-Ras oncogenic signal-
ing. The results demonstrate that the mechanism by which this
inhibitor blocks Ras-dependent signaling involves sequestering
Raf in the cytoplasm away from the plasma membrane where it
would be activated.
EXPERIMENTAL PROCEDURES
Synthesis of CAAX Analogues—The peptidomimetic FTI-276 was
synthesized as follows: 2-bromo-4-nitrotoluene was coupled with phen-
ylboronic acid. The product was oxidized with KMnO4 to 2-phenyl-4-
nitrobenzoic acid which was coupled with L-methionine methyl ester
followed by reduction with stannous chloride. The resulting 4-amino-2-
phenylbenzoyl methionine methyl ester was reacted with N-Boc-S-
trityl-cysteinal to give N-Boc-S-trityl methyl ester of FTI-276. This
methyl ester was hydrolyzed by LiOH and then deprotected by triflu-
oroacetic acid. The pure FTI-276 was obtained through preparative
HPLC. The peptidomimetic FTI-277 was made from the N-Boc-S-trityl
methyl ester of FTI-276 by first treatment with mercuric chloride fol-
lowed by hydrogen sulfide in methanol. The final product, FTI-277, was
obtained as its hydrochloride salt. Spectroscopic data of both FTI-276
and FTI-277 were consistent with their assigned structures. HPLC
analysis showed purity over 99.9%.
FTase and GGTase I Activity Assays—FTase and GGTase I activities
from 60,000 3 g supernatants of human Burkitt lymphoma (Daudi)
cells (ATCC, Rockville, MD) were assayed exactly as described previ-
ously (27). Inhibition studies were performed by determining the ability
of Ras CAAX peptidomimetics to inhibit the transfer of[3H]farnesyl
and [3H]geranylgeranyl from [3H]farnesyl pyrophosphate and
[3H]geranylgeranyl pyrophosphate to H-Ras-CVLS and H-Ras-CVLL,
respectively (27).
Ras and Rap1A Processing Assay—H-RasF, H-RasGG, pZIPneo, Raf,
S186 (31), and K-Ras4B cells (17) were seeded on day 0 in 100-mm
dishes in Dulbecco’s modified Eagle’s medium supplemented with 10%
calf serum and 1% penicillin/streptomycin. On days 1 and 2, cells were
refed with medium containing various concentrations of FTI-277 or
vehicle (10 mM DTT in Me2SO). On day 3, cells were lysed in buffer
containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 25 mg/ml leupeptin,
1 mM PMSF, 2 mM Na3VO4, 1 mg/ml soybean trypsin inhibitor, and 6.4
mg/ml Sigma-104® phosphatase substrate. Lysates were then immu-
noblotted using an anti-Ras antibody (Y13-238, ATCC) or an anti-
Rap1A antibody (SC-65, Santa Cruz Biotechnology, Santa Cruz, CA) as
described previously (27).
Co-immunoprecipitation of Raf and Ras—Cells were seeded on day 0
in 100 mM dishes, and on days 1 and 2 cells were treated with FTI-277
(10 mM) or vehicle. On day 3, cells were collected and pellets were
resuspended in ice-cold hypotonic buffer (10 mM Tris, pH 7.5, 5 mM
MgCl2, 1 mM DTT, 1 mM PMSF) and sonicated to break up the cell
pellet. The cell suspension was then centrifuged at 2,000 rpm for 10 min
to clear debris after which the supernatant was spun for 30 min at
100,000 3 g to separate membrane and cytosol fractions. The cytosol
and membrane fractions were then lysed as described previously (32).
Equal amounts of cytosol and membrane fractions were immunopre-
cipitated using 50 ml of a 25% protein A-Sepharose CL-4B suspension
(Sigma) with 1 mg/ml anti-c-Raf-1 (SC133, Santa Cruz Biotechnology,
Santa Cruz, CA). The samples were washed five times in 50 mM
HEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 0.1% Triton X-100, 10%
glycerol, 20 mM NaF). The final pellets were run on 12.5% SDS-PAGE,
transferred to nitrocellulose, and immunoblotted for the presence of Ras
using anti-Ras antibody (Y13-238) and anti-Raf antibody (SC133, Santa
Cruz Biotechnology, Santa Cruz, CA). Detection was the same as above
for Ras and Rap1A processing.
Detection of GTP and GDP Bound to Ras—H-RasF cells were seeded
and treated as above for Ras/Raf interaction studies. On day 2, however,
cells were labeled overnight with [32P]orthophosphate as described
previously (32). On day 3, the cytosol and membrane fractions were
separated, lysed, and equal amounts of lysate were immunoprecipitated
using anti-Ras antibody (Y13-259) along with 30 ml of protein A-agarose
goat anti-rat IgG complex (Oncogene Science). Bound nucleotide was
eluted and separated by TLC as described previously (32).
Raf-I Kinase Activity Assay—Raf-I kinase activity was assayed by
determining the ability of Raf to transfer phosphate from [g-32P]ATP to
a 19-mer peptide containing a Raf autophosphorylation site. Membrane
and cytosol fraction isolation and Raf immunoprecipitation were de-
scribed above. Immunoprecipitates were washed with kinase buffer (50
mM Tris, pH 7.3, 150 mM NaCl, 12 mM MnCl2, 1 mM DTT, 0.2% Tween
20). Immune complex kinase assays were performed by incubating
immunoprecipitates from membrane and cytosol fractions in 96 ml of
kinase buffer with 20 mCi of [g-32P]ATP (10 mCi/ml, Amersham Corp.)
and 2 ml of the Raf-1 substrate peptide IVQQFGFQRRASDDGKLTD (1
mg/ml, Promega, Madison, WI) for 30 min at 25 °C. The phosphoryla-
tion reaction was terminated by spotting a 50-ml aliquot onto Whatman
P81 phosphocellulose filters. The filters were washed in 0.5% or-
thophosphoric acid and air-dried. The amount of 32P incorporated was
determined by liquid scintillation counting.
MAP Kinase Immunoblotting—Cells were treated with FTI-277 and
lysed as described above for Ras and Rap1A processing. Equal amounts
of lysate were separated on a 15% SDS-PAGE, transferred to nitrocel-
lulose, and immunoblotted using an anti-MAPK antibody (erk2, mono-
clonal, Upstate Biotechnology, Inc., Lake Placid, NY). Antibody reac-
tions were visualized using peroxidase-conjugated goat anti-mouse IgG
and enhanced chemiluminescence detection (Amersham).
RESULTS AND DISCUSSION
Recently, we (20–22, 27) and others (23–26) have designed
Ras CAAX peptidomimetics that inhibit FTase potently with
concentrations in the nM range. However, these agents inhib-
ited Ras processing in whole cells only at mM levels (29, 30). In
order to investigate the mechanism of action of FTase inhibi-
tors, we sought to first improve the potency and selectivity of
our first generation of CAAX peptidomimetics. Structure activ-
ity relationship studies with CAAX peptides and peptidomi-
metics predict a hydrophobic region in the active site of FTase
that interacts with the central portion of the CAAX tetrapep-
tide. In our original designs (20–22), we have replaced the
central aliphatic dipeptide “VI” in CVIM by aromatic spacers of
the aminobenzoic acid family (Fig. 1A). Structural comparison
of CVIM with the peptidomimetic FTI-249 (Fig. 1A) suggests
that increased binding energy could be gained by increasing
the size and hydrophobicity of the aminobenzoic acid spacer to
fully occupy the FTase substrate binding pocket. In the present
work, we have designed FTI-276 and its methyl ester FTI-277
(Fig. 1A), where reduced cysteine and methionine are linked by
2-phenyl-4-aminobenzoic acid, hence increasing the hydropho-
bic character of the central portion of the peptidomimetic. FTI-
276 and FTI-277 were synthesized as described under “Exper-
imental Procedures.” Fig. 1B shows that FTI-276 inhibited
FTase with an IC50 of 500 pM, whereas FTI-249, the unsubsti-
tuted precursor to FTI-276, had an IC50 of 200,000 pM (27).
Thus, a phenyl ring at the 2 position of the aminobenzoic acid
spacer increased inhibition potency of FTase by 400-fold, indi-
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cating a significant role for the hydrophobic pocket within the
CAAX binding site of FTase. This extremely potent inhibitor
was also highly selective (100-fold) for FTase over the closely
related GGTase I. FTI-276 inhibited GGTase I with an IC50 of
50 nM (Fig. 1B). This 100-fold selectivity is superior to our
previously reported 15-fold selectivity of the parent compound
FTI-249 (27). We next determined the ability of FTI-276 to
inhibit Ras processing. To facilitate cellular uptake, we have
used the corresponding methyl ester, FTI-277 (Fig. 1A). H-
RasF cells (NIH 3T3 cells transformed with oncogenic (leucine
61) H-Ras-CVLS (31)) were treated with FTI-277 (0–50 mM),
and the lysates were blotted with anti-Ras or anti-Rap1A an-
tibodies as described under “Experimental Procedures.” Fig. 2A
shows that concentrations as low as 10 nM inhibited Ras proc-
essing but concentrations as high as 10 mM did not inhibit
processing of the geranylgeranylated Rap1A (Fig. 2A). FTI-277
inhibited Ras processing with an IC50 of 100 nM (Fig. 2A),
whereas the IC50 of FTI-249 was 100 mM. Furthermore, the
most potent CAAX peptidomimetics previously reported inhib-
ited Ras processing in whole cells at micromolar concentrations
(28–30). The selectivity of FTI-277 for farnesylation over gera-
nylgeranylation processing in whole cells was further investi-
gated by treating H-RasGG cells (NIH 3T3 cells transformed
with oncogenic (leucine 61) H-Ras-CVLL (31)) with FTI-277.
Fig. 2B shows that the processing of H-RasGG was not affected,
whereas that of H-RasF was completely blocked. Furthermore,
the processing of endogenous Ras was also blocked in pZIPneo
cells (NIH 3T3 cells transfected with empty vector) and Raf
cells (NIH 3T3 cells transfected with a transforming mutant of
human Raf-1 (Raf22W) (33)). Thus, FTI-277 is a farnesylation-
specific inhibitor which blocks the processing of both oncogenic
and normal Ras.
In order to determine the mechanism by which FTI-277
disrupts Ras oncogenic signaling, we transfected NIH 3T3 cells
with activated (GTP-locked) Ras and first investigated the
effects of FTI-277 on the interaction of Ras with its immediate
effector c-Raf-1 (1–3, 32). Various NIH 3T3 cell transfectants
(pZIPneo, H-RasF, H-RasGG) were treated with vehicle or FTI-
277, membrane and cytosolic fractions were isolated and im-
munoprecipitated with anti-Raf antibody, and the resulting
immunoprecipitates were blotted with anti-Ras antibody as
described under “Experimental Procedures.” Fig. 3 shows that
Raf did not associate with Ras in pZIPneo cells which do not
contain GTP-locked Ras. In contrast, H-RasF and H-RasGG
cells contain Ras-Raf complexes in the membrane but not in the
cytosolic fractions of untreated cells (Fig. 3). Treatment with
FTI-277 resulted in the accumulation of Ras-Raf complexes in
the cytoplasmic but not membrane fractions of H-RasF cells
(Fig. 3). The lack of Ras-Raf interaction at the cell membrane
and accumulation of these complexes in the cytoplasm occurred
only in Ras-F but not Ras-GG cells in agreement with the Ras
processing selectivity results of Fig. 2. Thus, our results dem-
onstrate that inhibition with FTI-277 results in the accumula-
tion of non-farnesylated cytosolic Ras that is capable of binding
to Raf. The fact that non-processed Ras can associate with Raf
in a non-membranous, cytoplasmic environment was confirmed
by transfecting NIH 3T3 cells with a GTP-locked Ras that lacks
a farnesylation site (Ras mutant with a leucine 61 oncogenic
mutation and a serine 186 mutation (34)) and, therefore, re-
mains in the cytoplasm. These cells were shown to contain only
cytoplasmic Ras-Raf complexes when immunoprecipitated with
Raf and blotted with anti-Ras antibodies (Fig. 3, S186). Thus,
farnesylation is not required for Ras to bind to Raf. Further-
more, the fact that non-farnesylated Ras binds Raf in the
cytoplasm gives support to an earlier suggestion that unproc-
essed GTP-locked Ras is a dominant negative form of Ras (35).
FIG. 1. Ras CAAX peptidomimetics and FTase/GGTase I inhi-
bition. A, structures of CVIM, FTI-249, FTI-276, and FTI-277. B,
FTase and GGTase I inhibition assays were carried out by determining
the ability of FTI-276 to inhibit the transfer of farnesyl and gera-
nylgeranyl to recombinant H-Ras-CVLS and H-Ras-CVLL, respectively.
The data are representative of at least three independent experiments.
FIG. 2. Effects of FTI-277 on Ras and Rap1A processing. A,
H-RasF cells were treated with various concentrations of FTI-277,
lysed, and the lysates were immunoblotted with anti-Ras or anti-Rap1A
antibodies as described under “Experimental Procedures.” B, pZIPneo,
H-RasF, H-RasGG, Raf, and S186 cells were treated with vehicle or
FTI-277 (10 mM), lysed, and lysates were immunoblotted by anti-Ras
antibody. Data are representative of five independent experiments.
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Since Raf binds Ras-GTP with much higher affinity than
Ras-GDP (1–3), we determined the nucleotide state of Ras in
the cytoplasmic Ras-Raf complexes as described under “Exper-
imental Procedures.” Fig. 4A shows that in H-RasF cells only
membrane fractions contained GTP-locked Ras. Upon treat-
ment with FTI-277, however, GTP-locked H-Ras was found
primarily in the cytosol (Fig. 4A). Thus, the cytoplasmic form of
H-Ras(61L) is still GTP-bound and can, therefore, still interact
with Raf. We next determined the Ser/Thr kinase activity of
Raf in Ras/Raf complexes by immunoprecipitating Raf and
assaying for its ability to phosphorylate a 19-mer autophospho-
rylated peptide. Fig. 4B shows that oncogenic H-RasF induced
activation of Raf at the plasma membrane and that treatment
with FTI-277 suppressed this activation. More importantly, the
cytoplasmic Ras/Raf complexes (Fig. 3) had basal levels of Raf
kinase activity that were comparable with those of the parental
NIH 3T3 cell line pZIPneo (Fig. 4B). Taken together, Figs. 3
and 4 demonstrate that oncogenic transformation with GTP-
locked H-Ras results in the constitutive recruitment of Raf to
the plasma membrane and its subsequent activation. Further-
more, FTase inhibition by FTI-277 suppresses this activation
by inducing the accumulation of Ras-Raf complexes in the
cytoplasm where Ras is GTP-bound, but Raf kinase is not
activated. The fact that Raf kinase is not activated when bound
to Ras in a non-membranous environment is consistent with
recent reports that indicate that Raf activation requires an as
yet unidentified activating factor at the plasmamembrane (36).
We then investigated the effects of FTI-277 on oncogenic Ras
activation of MAPK, a Raf downstream signaling event (1–3).
Oncogenic activation of MAPK can be easily detected, since the
phosphorylated activated MAPK migrates slower in SDS-
PAGE (29). Fig. 5A shows that NIH 3T3 cells transfected with
pZIPneo contain only inactive MAPK but that upon transfor-
mation with oncogenic H-Ras, MAPK is activated (Fig. 5A).
Pretreatment with FTI-277 results in a concentration-depend-
ent inhibition of the constitutive activation of MAPK by onco-
genic H-Ras. Concentrations as low as 300 nM were effective,
and the inhibition was complete at 1 mM. Taken together, Figs.
2 and 5 demonstrate that at least 50% but less than 100%
inhibition of H-Ras processing is required for inhibition of
MAPK activation. To determine whether the inhibition of
MAPK activation is due to selectively antagonizing H-Ras func-
tion we have used a series of NIH 3T3 cells lines transformed
with various oncogenes. Fig. 5B shows that FTI-277 was able to
block H-RasF but not H-RasGG activation of MAPK, and this is
consistent with its ability to inhibit H-RasF but not H-RasGG
processing. Selectivity of FTI-277 toward inhibition of Ras-de-
pendent activation of MAPK was substantiated by using NIH
3T3 cells, where MAPK is constitutively activated by transfor-
mation with the Raf oncogene (33). Fig. 5B shows that onco-
genic Raf activation of MAPK is not blocked by FTI-277, even
though processing of endogenous Ras was inhibited in these
cells (Fig. 2B). Taken together these results clearly demon-
strate that FTI-277 is highly effective and selective in disrupt-
ing constitutive H-Ras-specific activation of MAPK.
Since K-Ras4B, the predominant form of Ras mutated in
human tumors, is a much more efficient substrate (CAAX 5
CVIM) for FTase than is H-Ras (CAAX 5 CVLS) (13, 37), its
processing has been difficult to disrupt. To determine whether
or not FTI-277 inhibits K-Ras processing, we have treated
K-Ras4B cells (NIH 3T3 cells transformed with oncogenic (va-
line 12) K-Ras4B-CVIM (17)) with FTI-277 (0–30 mM). Fig. 6
FIG. 4. Effects of FTI-277 on Ras nucleotide binding and Raf
kinase activity. A, H-RasF cells were treated with vehicle or FTI-277,
lysed, and the lysates were immunoprecipitated with anti-Ras anti-
body. GTP and GDP were then released from Ras and separated by TLC
as described under “Experimental Procedures.” B, pZIPneo and H-RasF
cells were treated with vehicle or FTI-277, lysed, and cell lysates were
immunoprecipitated with an anti-Raf antibody. Raf kinase was assayed
as described under “Experimental Procedures.” Data are representative
of three independent experiments.
FIG. 3. Effects of FTI-277 on Ras/Raf association. pZIPneo, H-
RasF, H-RasGG, and S186 cells were treated with vehicle or FTI-277
(10 mM), homogenized, and the membrane and cytosolic fractions were
separated and immunoprecipitated by an anti-Raf antibody as de-
scribed under “Experimental Procedures.” The immunoprecipitates
were then resolved by SDS-PAGE and immunoblotted with anti-Ras
antibody. Data are representative of three independent experiments.
FIG. 5. Effect of FTI-277 on oncogenic activation of MAPK. A,
H-RasF cells were treated with various concentrations of FTI-277, cells
lysed, and lysates run on SDS-PAGE and immunoblotted with anti-
MAPK antibody as described under “Experimental Procedures.” B,
pZIPneo, H-RasF, H-RasGG, Raf, and S186 cells were treated with
vehicle or FTI-277 (10 mM), lysed, and cells lysates processed as for A.
Data are representative of two independent experiments.
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shows that FTI-277 inhibited K-Ras4B processing with an IC50
of 10 mM. Thus, inhibiting K-Ras4B processing (Fig. 6) requires
100-fold higher concentration than that needed for inhibition of
H-Ras processing (Fig. 2A). This lower sensitivity to FTI-277
could be because K-Ras4B-CVIM is a much better substrate
than H-Ras-CVLS (13, 37). An alternative explanation is that
K-Ras4B-CVIM could be geranylgeranylated (37), especially
when cellular FTase is inhibited. The fact that inhibition of
K-Ras4B processing occurs only at concentrations that inhibit
the processing of the geranylgeranylated Rap1A (Fig. 2A) is
consistent with this latter possibility. We next determined
whether the inhibition of K-Ras processing results in disrup-
tion of oncogenic K-Ras4B constitutive activation of MAPK.
The same cell lysates that were blotted with anti-Ras antibody
(Fig. 6) were reblotted with anti-MAPK antibody as described
under “Experimental Procedures.” Fig. 6 shows that NIH 3T3
cells that overexpress oncogenic K-Ras4B (17) contain mainly
hyperphosphorylated (activated) MAPK. Treatment of these
cells with FTI-277 (30 mM) inhibited oncogenic K-Ras4B consti-
tutive activation of MAPK (Fig. 6). Furthermore, consistent
with inhibition of Ras processing data (Fig. 6), higher concen-
trations were required to inhibit MAPK activation by K-Ras4B
as compared with H-Ras. Nevertheless, the data clearly dem-
onstrate for the first time that an FTase inhibitor disrupts both
H- and K-Ras processing and oncogenic signaling.
Thus, we have designed an extremely potent and highly
selective FTase inhibitor. FTI-277 inhibited H-Ras processing
with concentrations as low as 10 nM, and processing was
blocked by more than 95% at 3 mM. The most potent inhibitors
previously reported blocked H-Ras processing completely only
at 100 mM (28–30). The tremendous increase of potency in
intact cells is due to increased hydrophobicity of the central
portion of the peptidomimetic. FTI-277 inhibition of FTase
resulted in the accumulation of non-farnesylated, GTP-locked
H-Ras in the cytoplasm, where it was capable of binding Raf.
This sequestration of Raf in the cytoplasm prevented its re-
cruitment to the plasma membrane and subsequent activation.
Thus, non-farnesylated cytoplasmic H-Ras could act as a dom-
inant inhibitor by sequestering its downstream effector. Fur-
thermore, FTI-277 was very selective in antagonizing H-Ras-
specific signaling. The fact that FTI-277 suppressed only
H-RasF but not H-RasGG or Raf oncogenic signaling demon-
strates that the suppression is due to inhibition of H-Ras func-
tion and not the function of other farnesylated proteins that
may be required for H-Ras transformation. Finally, we demon-
strated for the first time that an FTase inhibitor can inhibit
K-Ras processing and signaling but at much higher doses than
required for H-Ras. Furthermore, we have recently demon-
strated that FTI-276 and FTI-277 inhibit tumor growth in nude
mice of a human lung carcinoma that has a K-Ras mutation
and a p53 deletion (38). Since the great majority of human
tumors with Ras mutations are of the K-type rather than the
H-type, this finding is critical to further development of these
agents as anti-cancer drugs.
Note Added in Proof—We have recently demonstrated that oncogenic
K-Ras4B processing and signaling are inhibited potently with a
GGTase I-specific inhibitor (39).
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FIG. 6. FTI-277 inhibits oncogenic K-Ras4B processing and ac-
tivation of MAPK. NIH 3T3 cells that overexpress oncogenic K-Ras4B
were treated with FTI-277 (0, 3, 10, and 30 mM), and the cell lysates
were immunoblotted with anti-Ras or anti-MAPK antibody as described
under “Experimental Procedures.” Data are representative of three and
two independent experiments, respectively.
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